UT- MD Anderson
Welcome,         Profile    Billing    Logout  
 18 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Naing, Aung
NCT04171219: Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Checkmark From Basket trial in combination with BXCL701 for solid tumor
Nov 2020 - Nov 2020: From Basket trial in combination with BXCL701 for solid tumor
Checkmark Efficacy data from Stage 1 of Basket trial in combination with BXCL701 for advanced solid tumors
Nov 2020 - Nov 2020: Efficacy data from Stage 1 of Basket trial in combination with BXCL701 for advanced solid tumors
Active, not recruiting
2
15
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Talabostat Mesylate, Val-boro-Pro
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
04/25
04/25
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT06567314: Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Recruiting
2
24
US
Ivonescimab
M.D. Anderson Cancer Center, Summit Therapeutics
Cutaneous Squamous Cell Carcinoma
09/28
09/30
NCT06651593: Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Not yet recruiting
2
40
US
SAR444881, Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals, Sanofi
Solid Tumors
09/28
09/30
NCT02721732: Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Checkmark For advanced cancers
Mar 2020 - Mar 2020: For advanced cancers
Active, not recruiting
2
157
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Paraganglioma, Metastatic Penile Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Small Cell Carcinoma, Stage III Adrenal Cortex Carcinoma AJCC v7, Stage IV Adrenal Cortex Carcinoma AJCC v7, Stage IV Penile Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Solid Neoplasm, Vascular Neoplasm
12/25
12/25
NCI-2018-01118, NCT03217747: Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients with Advanced Malignancies

Active, not recruiting
1/2
173
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Ivuxolimab, Anti-OX40 Agonist Monoclonal Antibody PF-04518600, PF-04518600, PF-8600, PF04518600, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Refractory Malignant Solid Neoplasm, Stage IV Prostate Cancer AJCC V8, Stage IVA Prostate Cancer AJCC V8, Stage IVB Prostate Cancer AJCC V8
09/25
09/25
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
NCT05672459: A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Recruiting
1/2
117
US
Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide, leukapheresis
M.D. Anderson Cancer Center, Invectys
Solid Tumor
06/26
12/29
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi, Sanofi Aventis Recherche & Développement
Solid Tumor
01/27
09/28
NCT02159989: Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed
1
83
US
Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Ziv-Aflibercept, Aflibercept, AVE0005, Eylea, Vascular Endothelial Growth Factor Trap, VEGF Trap, VEGF Trap R1R2, VEGF-Trap, Zaltrap
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
06/21
01/24
NCT04306224: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Completed
1
12
US, RoW
IMC-002
ImmuneOncia Therapeutics Inc.
Solid Tumor, Lymphoma
10/22
10/22
NCT04859777: A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Recruiting
1
70
US
MPT-0118, MPT-0118 + pembrolizumab
Monopteros Therapeutics Inc.
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
03/23
03/23
AURELIO-03, NCT04234113: Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Terminated
1
115
Europe, US, RoW
Nanrilkefusp alfa, SOT101, SO-C101, RLI-15, Pembrolizumab, KEYTRUDA®
SOTIO Biotech AG, SOTIO Biotech a.s.
Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
08/24
11/24
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
VICTORIA-01, NCT06163391: A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Recruiting
1
40
Europe, US, RoW
SOT201
SOTIO Biotech AG
Advanced Solid Tumor, Metastatic Solid Tumor
10/26
10/26
NCT01529593: Temsirolimus in Combination with Metformin in Patients with Advanced Cancers

Active, not recruiting
1
87
US
Temsirolimus, CCI-779, Torisel, Metformin
M.D. Anderson Cancer Center
Advanced Cancers
06/26
06/26
OR2-01, NCT06607939: ORB-021 In Patients With Advanced Solid Tumors

Recruiting
1
36
US
ORB-021
Orionis Biosciences Inc
Advanced Solid Tumors Cancer
12/26
02/27
NCT06563375: Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

Not yet recruiting
1
35
US
NP-101
M.D. Anderson Cancer Center
Solid Tumor
09/28
09/30
NCI-2015-00693, NCT02419495: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies

Terminated
1
221
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Eribulin, ER-086526, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Topotecan, Hycamptamine, Topotecan Lactone
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC V8, Stage III Renal Cell Cancer AJCC V8, Stage IIIA Lung Cancer AJCC V8, Stage IIIB Lung Cancer AJCC V8, Stage IIIC Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8, Stage IV Renal Cell Cancer AJCC V8, Stage IVA Lung Cancer AJCC V8, Stage IVB Lung Cancer AJCC V8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
09/24
09/24
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
NCT06046066: A Phase 1 Study of NM6603 in Advanced Solid Tumors

Recruiting
1
36
US
NM6603
NucMito Pharmaceuticals Co. Ltd.
Cancers
02/26
07/26
NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Recruiting
1
499
US
TAB004, JS004, Toripalimab, TAB001, JS001
TopAlliance Biosciences, Shanghai Junshi Bioscience Co., Ltd., CTI Clinical Trial and Consulting Services
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
03/26
03/26
Nguyen, Andrew
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
NCT04863495: Couples Lived Experience

Recruiting
N/A
600
US
NYU Langone Health, National Institute on Aging (NIA)
Alzheimer Disease, Dementia of Alzheimer Type
05/26
08/26
AgeWISE-AP, NCT06006962: Aging Well Through Interactions and Scientific Education - Action Plan

Recruiting
N/A
128
US
Aging Well through Interactions and Scientific Education - Action Plan, AgeWISE-AP
VA Office of Research and Development, VA Boston Healthcare System
Cognitive Aging
12/25
12/27
Liu, Qian
NCT05604859: Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Recruiting
4
350
RoW
Methylprednisolone, intravenous immunoglobulin, Tocilizumab, Low molecular weight heparin, conventional treatment
Qin Ning
Severe Fever With Thrombocytopenia Syndrome
12/23
06/24
NCT06009042: Efficacy of Intravenous Immunoglobulin in Patients With Hemorrhagic Fever With Renal Syndrome: a Prospective Study

Recruiting
4
100
RoW
IVIG 20g/d, IVIG 10g/d
Tongji Hospital
HFRS (Hemorrhagic Fever With Renal Syndrome)
06/24
06/24
NCT06154538: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Recruiting
2
170
RoW
Cadonilimab, 1, FOLFOX regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Colorectal Carcinoma
11/26
11/28
NCT06340061: The Aim of This Study is to Investigate the Correlation Between the Severity of Glaucoma and Corneal Biomechanics as Well as Anterior Chamber Parameters.

Active, not recruiting
N/A
80
RoW
Observational study
Henan Provincial People's Hospital
Glaucoma
12/24
12/24
NCT04850027: MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Recruiting
N/A
268
RoW
TME+Lateral lymph node dissection.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shengjing Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, West China Hospital, The First Affiliated Hospital of Dalian Medical University, China-Japan Friendship Hospital, Peking University First Hospital, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Beijing Cancer Hospital, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Tianjin People's Hospital, Second Affiliated Hospital of Suzhou University, Peking Union Medical College Hospital, Ruijin Hospital, First Hospital of China Medical University, Chinese PLA General Hospital, Zhejiang Cancer Hospital, The Affiliated Hospital of Xuzhou Medical University, The Affiliated Hospital of Qingdao University, Shanghai Cancer Hospital, China
Rectal Cancer
12/22
12/25
NCT06173414: Adaptive Optics ScanningLaser Ophthalmoscope Safety and Efficacy Clinical Trial

Completed
N/A
194
RoW
No intervention measures
Robotrak Technologies Co., Ltd.
Retinal Disease, Healthy
10/23
11/23
NCT06146946: Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)

Not yet recruiting
N/A
1384
RoW
Dissection of the No.253 lymph node, Omitting the dissection of the No.253 lymph node
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, China-Japan Friendship Hospital, Chinese PLA General Hospital, Ruijin Hospital, Fudan University, West China Hospital, Peking University Cancer Hospital & Institute
Rectal Cancer
12/26
12/29
NCT06011902: A 6-month Follow-up Study of Patients With Severe Fever With Thrombocytopenia Syndrome

Recruiting
N/A
1500
RoW
Tongji Hospital
Severe Fever With Thrombocytopenia Syndrome
12/23
03/24
NCT06020326: A Retrospective Cohort Study of HFRS

Recruiting
N/A
500
RoW
Tongji Hospital
HFRS
12/23
12/23
NCT06212934: "Chou's Tiaoshen" Acupoints for Short-term Insomnia.

Not yet recruiting
N/A
96
RoW
Acupuncture, Dry needle, Estazolam, Estazolam pill
Beijing Hospital of Traditional Chinese Medicine
Short-term Insomnia
03/25
05/25
NCT05923255: LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

Recruiting
N/A
568
RoW
LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）, TRH（Traditional Laparoscopic Right Hemicolectomy）
Zhejiang University
Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
05/26
05/31

Download Options